The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study
Open accessAbstract
BACKGROUND & AIMS: Liver fibrosis is the main determinant of long-term outcome in chronic liver diseases. Little is known about the prevalence of liver fibrosis in the general population. The aim of the study was to investigate the prevalence of liver fibrosis in the general adult population with unknown liver disease. METHODS: This was a population-based, cross-sectional study performed in the Barcelona metropolitan area. Subjects aged 18 to 75 years old were identified randomly from citizens included in the primary health care registry. Of 4866 subjects invited, 3076 participated (63.2%). Liver fibrosis was estimated by measuring liver stiffness (LS) with transient elastography (TE). Liver histology was assessed in 92 subjects with increased LS. RESULTS: Prevalence estimates of increased LS (≥6.8, ≥8.0, and ≥9.0 kPa) were 9.0%, 5.8%, and 3.6%, respectively. The etiology of liver disease was mainly nonalcoholic fatty liver disease (NAFLD), followed by alcohol risk consumption (consumption of ≥21 standard drinking units/wk in men and ≥14 standard drinking units/wk in women). Factors independently associated with increased LS were male sex, abdominal obesity, type 2 diabetes, serum glucose, high-density lipoprotein, and triglyceride levels. Subjects without risk factors for NAFLD or without alcohol risk consumption had a very low prevalence of increased LS. The best cut-off value of LS for significant liver fibrosis (F2-F4) was 9.2 kPa, with high sensitivity and specificity. TE was more accurate than alanine aminotransferase, NAFLD fibrosis score, or Fibrosis 4. An algorithm for screening for liver fibrosis using TE in the community setting is proposed. CONCLUSIONS: These findings show a high prevalence of silent liver disease with advanced fibrosis mainly related to NAFLD in adult European subjects without known liver disease. An LS value less than 9.2 kPa predicts the absence of significant liver fibrosis with high accuracy and could be used for screening purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., Abdelmalek, M. F., & Suzuki, A. (2019) · Hepatology · doi:10.1002/hep.30626 · Cited by 1,050
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Self-citationAdvances in non-invasive assessment of hepatic fibrosis
Loomba, R., & Adams, L. A. (2020) · Gut · doi:10.1136/gutjnl-2018-317593 · Cited by 345
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
Graupera, I., Thiele, M., Serra-Burriel, M., Caballeria, L., Roulot, D., Wong, G. L.-H., Fabrellas, N., Guha, I. N., Arslanow, A., Expósito, C., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.034 · Cited by 295
Self-citationGinès, P., Castera, L., Lammert, F., Graupera, I., Serra‐Burriel, M., Allen, A. M., Wong, V. W., Hartmann, P., Thiele, M., Caballeria, L., et al. (2022) · Hepatology · doi:10.1002/hep.32163 · Cited by 291
Self-citationImpact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Collagen biology and non‐invasive biomarkers of liver fibrosis
Karsdal, M. A., Daniels, S. J., Holm Nielsen, S., Bager, C., Rasmussen, D. G. K., Loomba, R., Surabattula, R., Villesen, I. F., Luo, Y., Shevell, D., et al. (2020) · Liver International · doi:10.1111/liv.14390 · Cited by 197
Serra-Burriel, M., Graupera, I., Torán, P., Thiele, M., Roulot, D., Wai-Sun Wong, V., Neil Guha, I., Fabrellas, N., Arslanow, A., Expósito, C., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.019 · Cited by 160
Self-citationPerformance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140
Lonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129
“As regards the relationship of sex with the development of fibrosis in general-population studies, data are conflicting in as much as they indicate no sex difference [23,27,28], or fibrosis as more prevalent in males when assessed with either (fibrosis 4) Fib4 [27] or liver stiffness [29].”
BackgroundIntegrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74
Åberg, F., Färkkilä, M., & Männistö, V. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14271 · Cited by 63
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Julián, M. T., Ballesta, S., Pera, G., Pérez-Montes de Oca, A., Soldevila, B., Caballería, L., Morillas, R., Expósito, C., Martínez–Escudé, A., Puig-Domingo, M., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1051958 · Cited by 30
Self-citationMazhari, S., Gitiara, A., Baghaei, K., Hatami, B., Rad, R. E., Asadirad, A., Joharchi, K., Tokhanbigli, S., Hashemi, S. M., Łos, M. J., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173263 · Cited by 22
Yang, L., Zhang, Y., Hong, X., Zhang, K., Liu, B., Zhang, P., Tang, Q., Yu, J., Jin, X.-Z., Jin, X.-Z., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03502-z · Cited by 7
Metadata
- Authors
- Caballería, L., Pera, G., Arteaga, I., Rodríguez, L., Alumà, A., Morillas, R. M., de la Ossa, N., Díaz, A., Expósito, C., Miranda, D., Sánchez, C., Prats, R. M., Urquizu, M., Salgado, A., Alemany, M., Martinez, A., Majeed, I., Fabrellas, N., Graupera, I., Planas, R., Ojanguren, I., Serra, M., Torán, P., Caballería, J., & Ginès, P.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 16
- Issue
- 7
- Pages
- 1138-1145.e5
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2785758228
- Cited by
- 276
- References
- 26
- FWCI
- 18.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.